【Objective】 To analyze the clinical efficacy of 450 nm blue laser vaporization in the treatment of benign prostatic hyperplasia (BPH) and to summarize the preliminary experience. 【Methods】 Clinical data of 30 BPH patients who underwent transurethral 450 nm blue laser vaporization at our hospital during Jun. and Sep. 2023 were selected. The operation time, hemoglobin decrease value, bladder irrigation time, catheterization time, and incidence of complications were recorded. The changes in the international prostate symptom score (IPSS), quality of life score (QoL), postvoid residual (PVR) volume, and maximum urinary flow rate (Qmax) were compared before and 3 months after surgery. 【Results】 All operations were successfully completed without conversion to transurethral resection of the prostate (TURP) or open surgery. The operation time was (38.2±7.5) minutes, the hemoglobin decrease value was (10.4±3.5) g/L 24 hours after surgery, the bladder irrigation time was (15.1±3.3) hours, and the catheterization time was (4.5±0.5) days. Compared to preoperative, 3 months after surgery, the IPSS \[(26.28±2.22) vs. (6.29±2.10)\], QoL \[(5.25±0.85) vs. (2.33±0.95)\], and PVR were decreased \[(397.89±8.47) mL vs. (15.62±2.17) mL\], while the Qmax was increased \[(8.15±2.09) mL/s vs. (19.50±2.51) mL/s\], with statistical significance (P<0.05). Mild bladder mucosal injury occurred in 2 cases (6.6%) during surgery, a second indwelling catheter was placed in 1 case (3.3%) after surgery, and gross hematuria occurred in 1 case (3.3%) after surgery. No serious complications occurred. 【Conclusion】 The use of 450 nm blue laser vaporization for the treatment of BPH has advantages of fast, efficient and reliable hemostasis, and low incidence of complications, which can effectively improve urination and is worthy of clinical promotion and application.